Loading
Latest filing published 19 Aug 2026 for 에이프릴바이오.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
서상준, listed as board member, appears in our data through filings on 에이프릴바이오 shares, published by DART (FSS). Over a trading history stretching from 3 September 2025 to 19 August 2026, the count stands at 6 filings.
Both buying and selling appear: 3 purchases worth €35k, against 3 sales. The totals do not cover 5 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 3 purchases and 1 sale.
The record was last updated on 19 August 2026 with an open-market purchase in 에이프릴바이오. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations